About Instytut Psychiatrii i Neurologii
Instytut Psychiatrii i Neurologii – ośrodek naukowo-badawczy i kliniczny z siedzibą w Warszawie, zajmujący się prowadzeniem badań własnych w zakresie psychiatrii i neurologii oraz koordynowaniem ich w skali kraju, ...
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
5
Wave Life Sciences Ltd.
5
Celgene
4
Idorsia Pharmaceuticals Ltd.
2
Alexion
1
Amgen
1
Celon Pharma SA
1
EMD Serono Research & Development Institute, Inc.
1
Genzyme, a Sanofi Company
1
Ipsen
1
Janssen Pharmaceutica N.V., Belgium
1
Clinical Trials at Instytut Psychiatrii i Neurologii
During the past decade, Instytut Psychiatrii i Neurologii conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 14 clinical trials were completed, i.e. on
average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 12 clinical trials were completed. i.e. 171.4%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
2002-12-01
2010-01-01
Completed
334
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
2012-09-18
2016-05-11
Completed
258
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
2012-10-24
2015-06-12
Completed
542
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
2013-10-01
2016-10-01
Completed
405
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
2014-02-20
2021-12-23
Completed
85
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
2013-12-03
2017-04-13
Completed
1,320
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
2014-09-01
2016-10-01
Completed
272
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Instytut Psychiatrii i Neurologii" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Wave Life Sciences Ltd." with 5 trials
sponsored, "Celgene" with 4 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored and "Alexion"
with 2 trials sponsored. Other sponsors include 9 different institutions and
companies that sponsored additional 19 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Psychiatrii i Neurologii"
#1 collaborator was "National Center for Research and Development, Poland" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Instytut Psychiatrii i Neurologii
According to Clinical.Site data, the most researched conditions in "Instytut Psychiatrii i Neurologii" are
"Huntington Disease" (4 trials), "Multiple Sclerosis" (4 trials), "Huntington's Disease" (3 trials), "Insomnia Disorder" (2 trials) and "Relapsing Multiple Sclerosis" (2 trials). Many other conditions were trialed in "Instytut Psychiatrii i Neurologii" in a lesser frequency.
Clinical Trials Intervention Types at Instytut Psychiatrii i Neurologii
Most popular intervention types in "Instytut Psychiatrii i Neurologii" are "Drug" (26 trials), "Other" (3 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (13 trials), "Interferon beta-1a" (3 trials), "Ozanimod" (3 trials), "Daridorexant 25 mg" (2 trials) and "Daridorexant 50 mg" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Instytut Psychiatrii i Neurologii
The vast majority of trials in "Instytut Psychiatrii i Neurologii" are
31 trials for "All" genders.
Clinical Trials Status at Instytut Psychiatrii i Neurologii
Currently, there are NaN active trials in "Instytut Psychiatrii i Neurologii".
undefined are not yet recruiting,
5 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 18 completed trials in Instytut Psychiatrii i Neurologii,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Instytut Psychiatrii i Neurologii, 6 "Phase 1"
clinical trials were conducted, 12 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 1 trials that are defined as “Not Applicable".
Departments of Instytut Psychiatrii i Neurologii
Instytut Psychiatrii i Neurologii has several departments that took part in Clinical trials: "Instytut Psychiatrii i Neurologii II Klinika Neurologiczna" - 11 trials
Departments List
Name
City
Trials